Micafungin: An evidence-based review of its place in therapy

Core Evidence

Volumn 9, Issue , 2014, Pages 27-39

  De La Torre, Pola ^a   Reboli, Annette C ^a  

^a Cooper Medical School Rowan University ^*  (United States)

Author keywords

Aspergillus; Candida; Echinocandin; Micafungin; Prophylaxis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ASPARTATE AMINOTRANSFERASE; CASPOFUNGIN; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID; NIFEDIPINE; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE;

ASPERGILLOSIS; CANDIDA; CANDIDEMIA; CANDIDIASIS; DEVICE INFECTION; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; ESOPHAGUS CANDIDIASIS; EVIDENCE BASED PRACTICE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOKALEMIA; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MEDICAL DEVICE; NAUSEA; NONHUMAN; PERITONITIS; REVIEW; SIDE EFFECT; VOMITING; ZYGOMYCOSIS;

EID: 84896948821     PISSN: 1555175X     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S36304     Document Type: Review

References (56)

1. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States,1980-1997. Clin Infect Dis. 2001;33(5):641-647. (Pubitemid 32762937)
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309-317. (Pubitemid 39050477)
3. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640-3645. (Pubitemid 41233011)
4. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect of outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60(3):613-618. (Pubitemid 47299877)
5. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1): 133-163. (Pubitemid 46167771)
6. Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-535.
7. Mycamine®(micafungin) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc; 2012.
8. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390): 1142-1151. (Pubitemid 37222342)
9. Eschenauer G, DePestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007;3(1):71-97.
10. Baddley JW, Moser SA. Emerging fungal resistance. Clin Lab Med. 2004;24(3):721-735, vii. (Pubitemid 39485871)
11. Park S, Kelly J, Kahn JN, et al. Specific substitutions in the echinocandin target Fksp1 account for reduced susceptibility of rare laboratory and clinical Candida species isolates. Antimicrob Agents Chemother. 2005;49(8):3264-3273. (Pubitemid 41060570)
12. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50(9): 2846-2856.
13. Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in health volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol. 2005;45(10): 1145-1152. (Pubitemid 41361914)
14. Tabata K, Katashima M, Kawamura A, Kaibara A, Tanigawara Y. Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections. Drug Metab Pharmacokinet. 2006;21(4): 324-331.
15. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin(FK463) in febrile neutropenic pediatric patients. Antimicrob Agents and Chemother. 2005;49(8): 3317-3324. (Pubitemid 41060577)
16. Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother. 2011;55(11):5107-5112.
17. Walsh TJ, Goutelle S, Jelliffe RW, et al. Intrapulmonary pharma-cokinetics and pharmacodynamics of micafungin in adult lung transplant recipients. Antimicrob Agents Chemother. 2010;54(8): 3451-3459.
18. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother. 2008;62(1):153-155. (Pubitemid 351865889)
19. Jacobson MJ, Steckelberg KE, Piper KE, Steckelberg JM, Patel R. In vitro activity of micafungin against planktonic and sessile Candida albicans isolates. Antimicrob Agents Chemother. 2009;53(6):2638-2639.
20. Simitsopoulou M, Peshkova P, Tasin E, et al. Species-specific and drug-specific differneces in susceptibility of Candida biofilms to echinocandins : characterization of less common bloodstream isolates. Antimicrob Agents Chemother. 2013;57(6):2562-2570.
21. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-1826.
22. Goodman JL, Winston DJ, Greenfield, RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845-851.
23. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545-1552.
24. van Burik JA, Ratanatharathorn V, Stepan, DE, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407-1416. (Pubitemid 39518200)
25. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93.
26. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol. 2000;110(2):273-284. (Pubitemid 30646851)
27. Toubai T, Tanaka J, Ota S, et al. Efficacy and safety of micafungin in febrile neutropenia patients treated for hematological malignancies. Intern Med. 2007;46(1):3-9. (Pubitemid 46062246)
28. Goto N, Hara T, Tsurumi H, et al. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol. 2010;85(4):872-876.
29. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis. 1995;27(6):613-617. (Pubitemid 26089493)
30. Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D; FK463 South African Study Group. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther. 2004;20(4):475-481. (Pubitemid 39120260)
31. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis. 2000;30(5):749-756.
32. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39(6):842-849. (Pubitemid 39244300)
33. de Wet NTE, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trail of micafungin(FK463) vs fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005;21(7):899-907. (Pubitemid 40477250)
34. Walsh TJ, Anaissie EJ, Denning DW, et al; Infectious Diseases Society of America. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3): 327-360. (Pubitemid 351265310)
35. Denning DW, Marr KA, Lau WM, et al. Micafungin(FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53(5):337-349. (Pubitemid 44524711)
36. Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis. 2008;11(1):89-93.
37. Mycamine®(micafungin) [European Medicine Agency prescribing information]. London: European Medicines Agency; 2013. Available from: www.ema.europa.eu/docs/en. Accessed November 13, 2013.
38. Andes DR, Safdar N, Baddley JW; Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54(8):1110-1122.
39. Kuse, ER, Chetchotisakd P, da Cunha C, et al; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 2007;369(9572):1519-1527. (Pubitemid 46670281)
40. Dupont BF, Lortholary O, Ostrosky-Zeichner, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care. 2009;13(5):R159.
41. Pappas PG, Rotstein F, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883-893. (Pubitemid 47580382)
42. Nucci M, Anaissie E, Betts RF, et al. Early removal of central venous catheter in patients with candidaemia does not improve outcome: analysis of 482 patients from 2 randomized clinical trials. Clin Infect Dis. 2010;51(3):295-303.
43. Shorr AF, Wu C, Kothari S. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. J Antimicrob Chemother. 2011;(66):375-380.
44. Cornely OA, Marty FM, Stucker F, Pappas PG, Ullmann AJ. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease. Mycoses. 2011;54(6):e838-e847.
45. Queiroz-Telles F, Berezin E, Leverger G, et al; Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Ped Infect Dis. 2008;27(9):820-826.
46. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005;24(10):654-661. (Pubitemid 41667052)
47. Cornely OA, Pappas PG, Young JA, Maddison P, Ullmann AJ. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. Expert Opin Drug Saf. 2011;10(2):171-183.
48. Arrieta AC, Madison P, Gross AH. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J. 2011;30(6):e97-e102.
49. Wilke M. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res. 2011;16(4):180-186.
50. Cornely OA, Sidhu M, Odeyemi I, van Engen AK, van der Wall JM, Schoeman O. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin. 2008;24(6):1743-1753. (Pubitemid 351929071)
51. Imataki O, Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T. Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis. Support Care Cancer. 2011;19(10):1657-1665.
52. Neoh CF, Liew D, Slavin M, et al. Economic evaluation of micafungin vs Liposomal Amphotericin B(LAmB) for the treatment of candidaemia and Invasive Candidiasis(IC). Mycosis. 2013;56(5):532-542.
53. Sidhu MK, van Engen, AK, Kleintjens J, Schoeman O, Palazzo M. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. Cur Med Res Opin. 2009;25(8):2049-2059.
54. Schonfeld W, Wang Cheng J, Tong KB, Seifeldin R. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clin Ther. 2008;30(5):964-973. (Pubitemid 351799867)
55. Sohn HS, Lee TJ, Kim J, Kim D. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther. 2009;31(5):1105-1115; discussion 1066-1068.
56. Zilberberg MD, Kothari S, Shorr AF. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care. 2009;13(3):R94.